2.5mg to ml semaglutide OZEMPIC PEN 0.25MG (2MG/3ML), 3ML NDC 00169418113 NON-RETURNABLE SHIP IN ICE Effect of Various Dosing Conditions

Many patients using semaglutide for type 2 diabetes or weight management wonder about flexibility in their weekly injection schedule

GLP-1 receptor agonists like semaglutide and tirzepatide offer a promising solution for individuals struggling with obesity or weight-related health conditions

POST-CARE Protecting Your Results Follow your prescribed plan consistently, including medications, nutrition, and lifestyle guidance

Do not combine the prescribed treatment with another GLP-1 medication unless specifically directed

STEP UP: In adults with obesity, along with diet and exercise, Wegovy HD (semaglutide) injection 7.2 mg: Designed to deliver greater weight-loss results than the Wegovy you know 1 Mean change in body weight (%) from week 0 to week 72 1 Co-primary end point 1 : Percentage of patients achieving 5% weight loss at 72 weeks: 88.7% of patients with Wegovy vs 38.3% with placebo HD Treatment regimen estimand: This estimand is based on the intention-to-treat principle and was used as the primary analysis method *Co-primary end point: % change in body weight for Wegovy HD vs placebo